Back to today’s briefing

Story perspectives

Doctors Warn: Ticagrelor May Increase Risks, Misreported Trials

6/20/2025

23 2

Summary

Story summary

Top doctors are raising alarms over ticagrelor, an anti-clotting medication from AstraZeneca, suggesting it may not only be ineffective but could also heighten risks for those suffering from acute coronary syndrome. A revealing BMJ investigation uncovered significant misreporting in clinical trials, casting shadows over its widespread use in the UK, where it is prescribed 45,000 times each month.

1 of 1

Story summary

Top doctors are raising alarms over ticagrelor, an anti-clotting medication from AstraZeneca, suggesting it may not only be ineffective but could also heighten risks for those suffering from acute coronary syndrome. A revealing BMJ investigation uncovered significant misreporting in clinical trials, casting shadows over its widespread use in the UK, where it is prescribed 45,000 times each month.